諾瓦瓦克斯醫藥(NVAX.US)Q2營收同比增長超7倍，八成營收來自政府合作開發合同
智通財經APP獲悉，諾瓦瓦克斯醫藥(NVAX.US)公佈2021年第二季度財報。財報顯示，公司Q2營收約爲2.98億美元，去年同期爲3553.8萬美元，同比增長約739%。Q2淨損失約爲3.52億美元，去年同期爲1752.1萬美元。基本和攤薄後每股淨損失爲4.75美元，去年同期爲0.3美元。
營收按類型劃分。財報顯示，主要營收來自與政府簽訂的藥物開發合同支持，相關收入約爲2.41億美元，其中在“曲率極速行動”（Operation Warp Speed，OWS）的合同中，共獲得政府約2.39億美元的資金。剩餘104.1萬美元則是來自與國防部簽訂的合同。在資金授予獲得的營收方面，公司共獲得來自流行病防備創新聯盟（CEPI）3195.5萬美元的授予資金收入，剩餘207.1萬收入則來自於其它組織資金授予。另外，公司共有2345.7萬美元收入是源自於版權稅的徵收。
該公司表示，已宣佈臨牀前數據的Nanoflu/nvx-cov2373聯合疫苗顯示出對流感和SARS-CoV-2病毒免疫反應的積極結果，預計今年晚些時候在澳大利亞啓動1期臨牀試驗。另一方面，牛津大學研究的瘧疾候選疫苗R21，將使用MATRIX-M™專利技術生產的佐劑。
新冠疫苗方面，公司已向印度藥品總監(DCGI)以及印度尼西亞和菲律賓的監管機構提交了監管文件，並預計將於2021年8月向世界衛生組織申請緊急使用清單。同時，公司預計將於2021年第三季度完成向英國藥品和保健產品監管局(MHRA)的監管備案，在向MHRA申請後的幾周內，在其他市場完成額外的監管申請，包括與歐洲藥品管理局(EMA)、澳大利亞治療品管理局、加拿大衛生部和新西蘭醫療安全管理局，並於今年第四季度向美國FDA提交緊急使用授權申請。
公司將於全球藥物廠家合作，預計有望在2021年第三季度末之前實現每月生產1億劑次疫苗，在2021年第四季度末之前提高到1.5億劑次。
財報公佈後，該公司股價盤後下跌9.4%，報213.99美元/股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
